National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 13 of 1999)

Overview

The National Health Act 1953, enacted by the Parliament of Australia, provides the legal framework for the administration of national health programs, including the Pharmaceutical Benefits Scheme (PBS). This Act was introduced to address the need for a structured and funded system to ensure the availability and affordability of prescription medications for Australians. The legislation allows for the regulation of drugs and medicinal preparations, ensuring they meet safety, quality, and efficacy standards. This legislative instrument, F2007B01105, made under the authority of the National Health Act 1953, specifically declares the cessation of certain drugs and medicinal preparations from the PBS as of 1 November 1999. The policy objective behind this declaration is to align the PBS with current medical practices and recommendations, ensuring that resources are allocated to treatments that offer the best therapeutic outcomes for patients.

Scope and Application

The Pharmaceutical Benefits Declaration under Subsection 85 (2AA) of the National Health Act 1953 applies to specific drugs and medicinal preparations listed in the Schedule of the declaration. The Act operates at the Commonwealth level, affecting the Pharmaceutical Benefits Scheme (PBS) managed by the Department of Health and Aged Care. This legislative instrument, made by the Assistant Secretary, Pharmaceutical Benefits Branch, designates particular substances, namely Clindamycin Palmitate Hydrochloride with Purified Water B.P., Dexamethasone Sodium Phosphate, Dihydrotachysterol, Procyclidine Hydrochloride, and Trimipramine Maleate, to be removed from the scope of Part VII of the National Health Act 1953. These substances will no longer be subject to the provisions governing the PBS, impacting how they are provided, reimbursed, and regulated within Australia. The declaration comes into effect on 1 November 1999 and does not explicitly mention any exclusions, exemptions, or thresholds beyond the substances specified in the Schedule. The application of the Act may be extended or restricted through subordinate instruments, although such details are not included in this particular declaration.

Key Provisions

The main operative sections of the legislative instrument F2007B01105, made under the National Health Act 1953, are found in the Declaration by Brett Anthony Lennon, the Assistant Secretary of the Pharmaceutical Benefits Branch of the Department of Health and Aged Care. This Declaration (subsection 85 (2AA)) follows advice from the Pharmaceutical Benefits Advisory Committee and specifies that certain drugs and medicinal preparations will no longer be subject to Part VII of the National Health Act 1953. The Declaration comes into effect on 1 November 1999 and lists the specific drugs that are to be removed from the scope of Part VII. These drugs include Clindamycin Palmitate Hydrochloride with Purified Water B.P., Dexamethasone Sodium Phosphate, Dihydrotachysterol, Procyclidine Hydrochloride, and Trimipramine Maleate, all of which are detailed in the Schedule to this instrument. The obligations imposed by this Act on the relevant parties primarily involve the cessation of the listed drugs from the Pharmaceutical Benefits Scheme (PBS), meaning they will no longer be subsidized under the scheme. This effectively removes these medications from the list of drugs covered by the Act. The obligations on the government and the Pharmaceutical Benefits Advisory Committee involve ensuring that the advice provided is thoroughly considered and that the necessary steps are taken to implement the changes as declared. This includes updating the Schedule of the National Health Act 1953 to exclude these medications, thereby affecting how they are regulated and reimbursed within the Australian healthcare system. Breaches of the provisions set out in this legislative instrument could lead to significant consequences. While the specific legislative instrument does not outline penalties for non-compliance, breaches of the National Health Act 1953 in general can result in both civil and criminal penalties. For example, contravening the Act can lead to fines and, in more severe cases, imprisonment. The exact penalties would depend on the specific nature of the breach and the provisions of the broader Act. The penalties for providing misleading or false information in the context of the PBS, for instance, could include fines up to several thousand dollars, and in cases of deliberate or reckless conduct, even more severe penalties could be imposed. These provisions underscore the importance of adhering to the requirements and obligations set out in the Act.